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Expression of miR-1, miR-133a, miR-133b and
miR-206 increases during development of human
skeletal muscle
Andrie Koutsoulidou1, Nikolaos P Mastroyiannopoulos1, Denis Furling2, James B Uney3 and Leonidas A Phylactou1*
Abstract
Background: MicroRNAs (miRNAs) are small RNA molecules that post-transcriptionally regulate gene expression
and have been shown to play an important role during development. miR-1, miR-133a, miR-133b and miR-206 are
expressed in muscle tissue and induced during muscle cell differentiation, a process that directs myoblasts to
differentiate into mature myotubes, which are organized into myofibers. Although miR-1, miR-133a, miR-133b and
miR-206 are well-studied in muscle, there is no information about their expression and function during human
development. The purpose of this study was to determine the profile of these miRNAs in muscle cells isolated
from different stages of human development.
Results: We examined the levels of miR-1, miR-133a, miR-133b and miR-206 during the development of human
foetus. All four miRNA levels were found increased during late stages of human foetal muscle development.
Increases in the expression levels of these miRNAs were proportional to the capacity of myoblasts to form
myotubes. Changes in miRNA levels during human foetal development were accompanied by endogenous
alterations in their known targets and also in their inducer, MyoD. Ectopic MyoD expression caused an induction of
muscle cell differentiation in vitro, accompanied by an increase in the levels of miR-1, miR-133a, miR-133b and miR-
206.
Conclusions: This study provides data about the profile of four miRNAs in human muscle cells isolated during
different stages of foetal development. These results may shed light on the differentiation of muscle cells and
regulation of muscle formation through miRNAs, during the development of human foetus.
Background
MicroRNAs (miRNAs) are small (~22 nucleotides) non-
coding RNAs that negatively regulate gene expression at
the post-transcriptional level [1,2]. miRNAs bind to the
3’ untranslated region (3’UTR) of their target mRNAs,
causing either inhibition of protein translation or
mRNA degradation [2]. During the last few years,
intense research has revealed the regulatory role of miR-
NAs in almost all cellular processes, during health and
disease [3-6].
Skeletal myogenesis is a complex and tightly regulated
developmental process that directs myoblasts to differ-
entiate into mature myotubes. During myogenesis,
myoblasts are stimulated to initiate the expression of
myogenic differentiation-specific genes, withdraw from
cell cycle and fuse together to form multinucleated
myotubes, which are ultimately organized into myofibers
[7]. Myogenesis occurs during embryogenesis in order
to form muscle and in adults to replace lost or damaged
muscle. Most embryonic skeletal myogenic progenitors
arise from somites, which are masses of paraxial meso-
derm distributed along the two sides of the neural tube
[8]. Somites differentiate along the dorsal-ventral axis to
give rise to the dorsally located epithelial dermomyo-
tome and the ventrally located mesenchymal sclerotome
[8]. The dermomyotome gives rise to musculature and
dermis, whereas the sclerotome develops into the carti-
lage and bone. Myogenic precursors confined in the
epithelium of the dermomyotome express Pax3, Pax7
and low levels of the myogenic determination factor
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Myf-5. Delamination of muscle progenitor cells from the
dermomyotome causes the formation of the myotome,
the third somitic compartment, which contains the first
differentiated myofibers [9]. During the late stages of
embryogenesis, a specialized population of myogenic
stem cells, termed satellite cells, arise in order to pro-
vide most of the myonuclei to adult muscles during the
postnatal growth of muscle tissue [8].
There has been an ever growing number of miRNAs
found to be expressed in muscle tissue. Of these, the
most extensively studied are miR-1, miR-133 and miR-
206. miR-1 and miR-133 are highly expressed both in
skeletal and cardiac muscles, whereas miR-206 is specifi-
cally expressed only in skeletal muscle [10,11]. In human
and mouse, these miRNAs are encoded by three loci,
each of which produces a bicistronic transcript, contain-
ing one miRNA from the miR-1/206 family and one from
the miR-133 family (miR-133a, miR-133b) [10].
All four muscle miRNAs are induced during muscle
differentiation, implying a critical role in the regulation
of the process [10,11]. The expression of these miRNAs
was found to be regulated by key myogenic regulatory
factors (MRFs), including myogenic differentiation 1
(MyoD), myogenin [12], myocyte enhancer factor 2
(MEF2) [13] and serum response factor (SRF) [10].
Although miR-1, miR-133 and miR-206 are related in
terms of expression, they have different targets, biologi-
cal functions and transcriptional activation [4,10,14-17].
Cell culture experiments have shown that miR-1 and
miR-206 promote muscle cell differentiation, whereas
miR-133 promotes cell proliferation by down-regulation
of different target genes [10,11].
Currently there is very little information about the
expression and function of muscle-specific miRNAs in
development and specifically in human development.
The purpose of this study was to investigate the expres-
sion of miR-1, miR-133a, miR-133b and miR-206 at dif-
ferent stages of the human developing muscle and
during differentiation in myoblast cell lines. The levels
of all four miRNAs were found proportional to the stage
of muscle development. Moreover, all four miRNAs
were found elevated during in vitro differentiation of
myoblasts to myotubes. Increases in the levels of these
miRNAs were accompanied by alterations in their
known targets and also in their inducer, MyoD. Finally,
overexpression of MyoD in these cells caused an
increase in muscle cell differentiation in vitro and an
induction of muscle miRNA gene expression.
Results and discussion
Human myoblasts from later stages of development have
an increased capacity to differentiate
Although there are many reports regarding human mus-
cle development, there is limited information about the
capacity of isolated myoblasts to differentiate in vitro into
mature myotubes during different stages of muscle foetal
development [18]. The capacity of myoblasts, isolated
from different stages of the development of human foetus
to differentiate into myotubes was first examined. For
this study, human myoblasts were used from cell lines of
three different developmental stages of the foetus (12-
week old human foetus, 14-week old human foetus and
newborn). Following in vitro differentiation induction,
myoblasts isolated from 12-week old human foetus
showed very little myotube formation (Figure 1A). Simi-
lar results were obtained with 14-week old foetal myo-
blasts even if a slightly increased capacity to form
myotubes was observed when compared to 12-week old
myoblasts. In contrast, myoblasts isolated from newborn
displayed the highest capacity to form mature multinu-
cleated myotubes. Muscle cell differentiation was further
characterised and proved that formation and maturity of
myotubes was significantly higher in the newborn cell
line compared to the foetal cell lines (Figure 1B).
miR-1, miR-133a, miR-133b and miR-206 levels are
proportional to the stage of muscle development
There is currently no existing evidence about the expres-
sion of miR-1, miR-133a, miR-133b and miR-206 genes
during the stages of human muscle development. miRNA
levels were compared between the three myoblast cell
lines from different stages of human foetal development
(12-weeks, 14-weeks and newborn). Each of the four
miRNAs showed a similar expression pattern in the three
stages of muscle development, which is probably due to a
similar mechanism of regulation. There was a steep
increase in all four miRNA levels in cells isolated from
the newborn, compared to cells isolated from 12-week
and 14-week old foetuses (Figure 2). Moreover, there was
a slight increase in the miRNA levels in cells isolated
from the 14-week old foetus, compared to those of the
12-week old foetus (Figure 1 and Table 1). These data
are consistent with previous findings that miR-1 and
miR-133 are expressed in very small amounts in the
developing heart and skeletal muscle of embryonic day
13.5 (E13.5) and E16.5 in mice and their expression
increases in neonatal heart and skeletal muscle [10]. A
similar observation regarding the increase of muscle-spe-
cific miR-206 during mouse embryonic development was
recently reported [19]. Furthermore, these data agree
with findings in zebrafish, showing that most miRNAs
are expressed relatively late during embryogenesis [20].
miR-1, miR-133a, miR-133b and miR-206 were found
to be expressed during muscle cell differentiation both
in adult primary human myoblasts and adult mouse cell
lines [10-12]. Isolated myoblast cell lines were examined
for the induction of these miRNAs during differentia-
tion. miR-1, miR-133a, miR-133b and miR-206 levels
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were low in undifferentiated myoblasts, signifying that
they are not highly expressed during the stages before
differentiation (Figure 2). On the contrary, when cells
were induced to differentiate in vitro, a marked increase
was observed in the levels of all four miRNAs, suggest-
ing their active role in the process (Figure 2). These
results agree with previous work performed on adult
mouse cell lines and adult primary human myoblasts
[10-12].
The expression patterns of miRNAs in the various
stages of muscle development are proportional to the
differentiation levels seen in these cells. It can be there-
fore assumed that miR-1, miR-133a, miR-133b and miR-
206 levels correlate with the induced in vitro differentia-
tion of myoblasts to myotubes. The relationship between
the four miRNAs and differentiation, during human
development is analogous to that shown in adult human
and mouse muscle cells [10-12].
Figure 1 Muscle cell differentiation increases during the late stages of foetal development. (A) Muscle cell differentiation was detected in
all three human myoblast cell lines (12-week old, 14-week old and newborn) by immunocytochemistry against myosin heavy chain (MyHC).
DAPI was used to stain cell nuclei. Scale bar, 0.8 mm. (B) Muscle formation was characterized by measuring or calculating (i) the average number
of myotubes per area (initial cell fusion), (ii) the percentage of nuclei present in myotubes compared to the total number of nuclei present in
each area (fusion index %) and (iii) the average number of nuclei per myotube (myotube maturation) in total 10 areas of cells.
Koutsoulidou et al. BMC Developmental Biology 2011, 11:34
http://www.biomedcentral.com/1471-213X/11/34
Page 3 of 9
Alterations in muscle-specific miRNA known targets and
inducer levels during human muscle development
Although miR-1, miR-133a, miR-133b and miR-206
genes have similar expression patterns, they have differ-
ent targets and biological functions [4,10]. Among the
four miRNAs, miR-1 and miR-206 were found to pro-
mote muscle cell differentiation [10,11]. miR-1 was
shown to bind to the 3’UTR of the histone deacetylase 4
(HDAC4), an inhibitor of muscle differentiation, and
suppresses its expression during growth and differentia-
tion conditions [10,21,22]. Connexin 43 (Cx43), a gap
junction channel required in embryonic skeletal muscle,
which is also down-regulated during late embryogenesis
and early post-natal life was found to be an experimen-
tally verified target of miR-206 and miR-1 during myo-
genesis [15].
Figure 2 Muscle miRNA expression levels increase during muscle foetal development. 12-week and 14-week old foetal and newborn
human myoblasts were grown to confluency or induced to differentiate for 5 days. miR-1 (A), miR-133a (B), miR-133b (C) and miR-206 (D) levels
were significantly higher in newborn myotubes compared to foetal myotubes. miRNA levels were found to be low in confluent cells.
Table 1 Statistical analysis of muscle miRNA expression levels during muscle foetal development
miR-1 ΔCt miR-133a ΔCt miR-133b ΔCt miR-206 ΔCt
Comparison between confluent and differentiated cells 12 weeks p < 0.05 p < 0.05 p < 0.05 p < 0.05
14 weeks p < 0.05 p < 0.05 p < 0.05 p < 0.05
Newborn p < 0.05 p < 0.05 p < 0.05 p < 0.05
Comparison between confluent and differentiated cells (all developmental stages
combined)
p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001
Comparison between developmental stages (differentiated cells) p < 0.05 p < 0.05 p < 0.005 p < 0.005
Comparison of miRNA levels between confluent and differentiated muscle cells at each developmental stage or combined was performed. Comparison of miRNA
levels between developmental stages of differentiated muscle cells was carried out. All results were statistically significant (p-value < 0.05).
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Protein analysis showed a reduction in the protein
levels of HDAC4 and Cx43 in newborn muscle cells
compared to the two foetal cell lines (Figure 3A and
Figure 3B). These results are analogous to the elevated
miR-1 and miR-206 levels observed in the newborn
muscle cell line in part 3.2 (Figure 2).
MyoD is a master myogenic transcriptional regula-
tory factor that activates a number of muscle-specific
genes to drive muscle cell differentiation [23]. It is
required at initial stages of myogenesis for the com-
mitment of multipotential somite cells to the myogenic
lineage [24]. MyoD is also expressed in proliferating
myoblasts thus regulating the transition from prolifera-
tion to differentiation [25]. Experiments on adult
mouse C2C12 and mouse embryonic fibroblasts
showed that MyoD binds to regions upstream of miR-
1, miR-133a and miR-206 and regulates their expres-
sion [12,14]. As expected, MyoD levels were elevated
in the newborn cell line, compared to the foetal cell
lines (Figure 3C). This finding comes into agreement
with the observations that newborn myoblasts can
form more myotubes and have elevated miRNA levels
(Figure 1 and Figure 2).
Restoration of decreased MyoD levels promotes muscle
cell differentiation in vitro and increases miR-1, miR-133a,
miR-133b and miR-206 gene expression in human foetal
myoblasts
Forced expression of MyoD in non-muscle cells in cul-
ture can induce myogenic differentiation, whereas
MyoD-null primary myoblasts exhibited reduced differ-
entiation [26,27].
Foetal cell lines displayed low levels of muscle cell
differentiation, accompanied by low expression levels
of MyoD and miRNAs (Figures 1, 2 and Figure 3C). In
order to induce muscle cell differentiation in 12-week
and 14-week old foetal myoblast cell lines and deter-
mine whether miRNA levels will also be stimulated,
cells were transfected with an adenovirus expressing
the MyoD transcription factor (AdM) (Figure 4A). In
situ analysis of myotube formation showed an increase
in their ability to form myotubes in both 12-week and
14-week old foetal muscle cell lines in MyoD-trans-
fected cells, compared to control cells (Figure 4B and
Figure 4C).
Levels of miR-1, miR-133a, miR-133b and miR-206
were next investigated in MyoD-transfected cells.
Following differentiation, all four miRNAs were
found significantly increased in MyoD-transfected
cells from both cell lines, compared to control cells
(Figure 5).
These results suggest a mechanism by which MyoD
induces in vitro muscle cell differentiation in human
foetal cells, accompanied by the induction of miR-1,
miR-133a, miR-133b and miR-206 levels in vitro.
Conclusions
Although miR-1, miR-133a, miR-133b and miR-206
have been extensively studied, there is no information
about their expression during the development of
human skeletal muscle. Results presented in this study
show that miR-1, miR-133a, miR-133b and miR-206 are
induced during human muscle cell differentiation and
their levels are increased proportionally to the stage of
muscle foetal development. Since miRNAs regulate
important processes during development, such informa-
tion would be very important for understanding the
mechanism of muscle formation during foetal develop-
ment. Results presented in this work can provide
insights of muscle cell differentiation during the devel-
opment of human foetus and offer valuable information
about the implication of miRNAs in congenital
myopathies.
Figure 3 Alterations in miRNA targets and inducer in muscle
cells during development. Western blot analysis showed increased
levels of HDAC4 (A), a verified target of miR-1, and Connexin 43 (B),
a verified target of miR-206 and miR-1 in foetal muscle cells,
compared to newborn cells. Western blot analysis of MyoD (C), an
inducer of all four miRNAs, showed decreased levels in foetal
muscle cells compared to newborn cells.
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Figure 4 MyoD induces myotube formation in human foetal muscle cells. (A) Overexpression of endogenous MyoD levels were detected
by Western blotting in 12-week old (i) and 14-week old (ii) muscle cells, transfected with the MyoD adenovirus (AdM), compared to adenovirus-
control transfected cells (AdC) and untransfected cells (Un). (B) Immunocytochemistry of the myogenic marker myosin heavy chain (MyHC)
showed a marked increase in myotube formation in cells overexpressing MyoD, compared to control cells. Nuclei were stained with DAPI. Scale
bar, 0.8 mm. (C) Overexpression of MyoD resulted in increased levels of MyHC levels, as detected by Western blotting, in 12-week old (i) and 14-
week old (ii) muscle cells, compared to control cells.
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Figure 5 MyoD induces miRNA levels in human foetal muscle cells. A significant increase in the levels of all four miRNAs was detected by
Real-Time PCR in 12-week old (A) and 14-week old (B) MyoD-transfected muscle cells, following differentiation, compared to control-transfected
and untransfected cells. Statistical analysis comparing the differentiated AdM, AdC and untransfected miRNA levels revealed significant
differences with the corresponding p-values indicated in each graph.
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Methods
Human skeletal muscle cell culture and adenovirus
transfections
Human myoblasts were isolated under sterile conditions
from muscle biopsies which showed no signs of neuro-
muscular disease. The biopsies were obtained from the
Tissue Bank for Research (BTR) of the Association
Francaise contre les Myopathies in accordance with the
French legislation on ethical rules and the local
Bioethics Committee. For foetuses (12 and 14 weeks of
development), biopsies were taken from the proximo-
ventral region of the limb, which gives rise to the quad-
riceps [18]. For the newborn infant (5 days after birth),
the biopsy was taken from the quadriceps [28]. The
stage of development was calculated for each foetus at
the autopsy and based on morphometric analysis of the
head, femur and foot. For the infant, the age was calcu-
lated from birth.
Myoblasts were grown in Dulbecco’s Modified Eagle
Medium (DMEM) (Invitrogen) supplemented with 20%
Foetal Bovine Serum (FBS) (Invitrogen) (growth med-
ium). Medium was changed every day. When cells
reached confluency, they were differentiated with
DMEM supplemented with 2% Horse Serum (Invitro-
gen) (differentiation medium) for 5 days or processed as
mentioned elsewhere. In the case of MyoD adenovirus
transfections, 2 days before confluency, myoblasts were
transfected with 100 M.O.I. of human MyoD adenovirus
(Vector Biolabs) (AdM) or control virus (Vector Biolabs)
(AdC), expressing a non-specific target, left to grow to
confluency and then induced to differentiate or pro-
cessed as explained elsewhere.
miRNA analysis
Total RNA enriched with small RNAs, including miR-
NAs, was extracted from muscle cells at confluency or
after 5 days of differentiation, using mirVana™
miRNA Isolation Kit (Ambion). The extracted RNA
was subjected to Reverse Transcriptase PCR using the
TaqMan® MicroRNA Reverse Transcription Kit
(Applied Biosystems). miRNA levels were measured by
Real-Time PCR amplification using TaqMan® Micro-
RNA Assays specific for miR-1, miR-133a, miR-133b
and miR-206 (Applied Biosystems), according to the
manufacturer’s instructions. miRNA expression was
normalized to the RNA U6B small nuclear (RNU6B)
(Applied Biosystems).
Immunocytochemistry
Differentiated cells were fixed in 4% parafolmaldehyde
and incubated with a monoclonal MY32 antibody
against myosin heavy chain (MyHC) (Sigma) and a
Texas-red-conjugated anti-mouse secondary antibody
(Jackson Laboratories). Nuclei were stained with DAPI
(Vysis). Images were captured with a NIKON digital
camera and then assembled using Adobe Photoshop
software. Myotubes were counted three times for each
cell line from ten different areas of cells.
Western Blotting
Confluent myoblasts or differentiated muscle cells were
subjected to protein extractions. 40 - 60 μg of protein
extracts were incubated with HDAC4 (1:200, Santa
Cruz), Connexin 43 (1:200, Santa Cruz), MyoD (1:300,
Santa Cruz), MyHC (1:300, Sigma) or GAPDH (1:1500,
Santa Cruz) primary antibodies, followed by incubation
with goat anti-mouse IgG or donkey anti-rabbit IgG sec-
ondary antibodies conjugated to horseradish peroxidase
(Santa Cruz).
Statistical analysis
Statistical analysis was performed as described before
[29], using SAS, v 9.1 (SAS Institute Inc., Cary, NC,
USA) software. ΔCt values were calculated as the Ct
(miRNA) - Ct(RNU6B). Exact Wilcoxon tests were used
to compare the ΔCt parameters. Analyses were per-
formed both at each developmental stage (12 weeks, 14
weeks and newborn) and for all stages combined. A p-
value of below 0.05 was considered statistically signifi-
cant. All probabilities were two-tailed.
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